HLINOMAZ, Ota. Role of Plasma Neutrophil Gelatinase Associated Lipocalin as a New Biomarker. Journal of Critical Care Medicine. Warsaw: De Gruyter Oopen LTD, 2016, vol. 2, No 1, p. 56-57. ISSN 2393-1809. Available from: https://dx.doi.org/10.1515/jccm-2016-0004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Role of Plasma Neutrophil Gelatinase Associated Lipocalin as a New Biomarker
Authors HLINOMAZ, Ota (203 Czech Republic, guarantor, belonging to the institution).
Edition Journal of Critical Care Medicine, Warsaw, De Gruyter Oopen LTD, 2016, 2393-1809.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Poland
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/16:00093376
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1515/jccm-2016-0004
UT WoS 000372807600009
Keywords in English Plasma Neutrophil Gelatinase
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 3/2/2017 10:31.
Abstract
I read with interest the study of Raluca Fodor et al., on the significance of Plasma Neutrophil Gelatinase-Associated Lipocalin (NGAL), as an early biomarker for acute kidney injury in critically ill patients, published recently in issue no.4/2015 of JCCM journal [1]. In this well-written and interesting study, the authors successfully demonstrated that in critically ill patients, increased levels of NGAL predict, with a good sensitivity and specificity, the development of acute kidney injury within forty-eight hours of admission to an ICU. However, as no information is presented on the aetiology of the acute kidney injury, we believe that the article raises interesting and still un-elucidated hypotheses on the pathophysiological substrate of the systemic release of NGAL in patients with critical conditions.
PrintDisplayed: 7/10/2024 04:18